Minister Carroll MacNeill TD Announces Major Investment in Medicines at Clinical Trials Conference

Minister for Health Jennifer Carroll MacNeill TD delivered the closing address at the recent Conference on Clinical Trials and Access to Medicines, highlighting Ireland's ambition to be a leading location for clinical research while ensuring patients can access innovative treatments as quickly as possible.

Addressing delegates from across the healthcare, research, pharmaceutical and patient advocacy sectors, the Minister spoke about the transformative role of clinical trials in advancing medical knowledge, improving patient outcomes and providing earlier access to potentially life-changing therapies. She emphasised the importance of fostering innovation, strengthening research capacity and ensuring that Ireland remains an attractive destination for clinical research and investment.

In her closing remarks, Minister Carroll MacNeill TD announced the establishment of a new National Medicines and Health Technology Investment Mechanism, designed to support timely patient access to new medicines and emerging health technologies while ensuring the long-term sustainability of the health service.

The announcement coincides with a €324 million increase in funding for medicines, bringing Ireland's total annual medicines expenditure to more than €4 billion. The Minister also highlighted that Budget 2027 has earmarked €30 million specifically for new medicines, representing a significant investment in improving access to innovative treatments for patients across the country.

Speaking at the conference, Minister Carroll MacNeill said that Ireland must continue to harness the opportunities presented by research, innovation and collaboration, while ensuring that patients remain at the centre of decision-making.

The conference provided an important platform for discussion on the future of clinical trials, medicines policy and healthcare innovation, reinforcing Ireland's commitment to delivering better health outcomes through research and access to cutting-edge treatments.